Edwards Lifesciences Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) decreased by 21.9% to $197.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 138.6%, from $82.70M to $197.30M. Over 2 years (FY 2023 to FY 2025), Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) shows an upward trend with a 102.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An unexplained increase may signal inefficiencies in collections or a buildup of non-core assets, while a decrease generally reflects effective management of miscellaneous receivables.
This represents amounts owed to the company from non-core business activities, excluding standard trade receivables from...
Standard line item across most industries; peers typically group this under other current assets.
current_assets_other_receivables_net_current| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $61.80M | $59.30M | $56.10M | $95.50M | $118.30M | $82.70M | $205.60M | $199.50M | $252.50M | $197.30M |
| QoQ Change | — | -4.0% | -5.4% | +70.2% | +23.9% | -30.1% | +148.6% | -3.0% | +26.6% | -21.9% |
| YoY Change | — | — | — | — | +91.4% | +39.5% | +266.5% | +108.9% | +113.4% | +138.6% |